Understanding and overcoming resistance to melanoma immunotherapy
Project 3: Modeling and overcoming resistance to melanoma immunotherapy
This study is looking into why some melanoma patients don’t respond well to certain immunotherapy treatments and hopes to find new ways to make these treatments work better for everyone.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-10878835 on NIH RePORTER |
What this research studies
This research investigates the biological mechanisms that cause resistance to melanoma treatments that use immunotherapy, specifically anti-PD-1/L1 therapy. By developing laboratory models, the team aims to identify how these resistance mechanisms work at a molecular level. The research will explore potential combination therapies that could enhance the effectiveness of existing treatments, including activating immune responses and natural killer cells. The ultimate goal is to improve patient care by translating these findings into better treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are melanoma patients who have experienced primary or acquired resistance to anti-PD-1/L1 therapy.
Not a fit: Patients with melanoma who have not undergone immunotherapy or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma patients who currently do not respond to immunotherapy.
How similar studies have performed: Previous research has shown promise in understanding and overcoming resistance mechanisms in cancer therapies, suggesting that this approach could yield valuable insights.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Ribas, Antoni — University of California Los Angeles
- Study coordinator: Ribas, Antoni
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.